Distribution Agreement with Arthrex GmbH.
CROMA-PHARMA GmbH has signed a comprehensive distribution agreement with the family-owned medical device company Arthrex GmbH. With this agreement CROMA-PHARMA secured the integration of the market-leading PRP (platelet rich plasma) technology into its growing aesthetic product portfolio. The agreement entered into force April 1st 2017. The exclusive distribution rights for aesthetic applications of the Arthrex ACP® double-syringe technology relate to the European countries Austria, France, Poland, Spain, Portugal, the Netherlands and Romania.
Platelet rich plasma (platelet-rich plasma) has been successfully used in aesthetic medicine, e.g. for skin rejuvenation, for hair loss, as well as for plastic surgery, and enjoys great popularity.
The advantages of the Arthrex ACP® double syringe:
- Two syringes in one: Innovative design for easy production of PRP.
- 100% autolog. The blood does not react with synthetic release gel or anticoagulants, nor with exogenous activators, e.g. Calcium gluconate.
- Speed: PRP can be manufactured and applied with the Arthrex ACP® double syringe within a few minutes.
- Safety: The Arthrex ACP® double syringe provides a closed, sterile system for use in practice and surgery.
This system, which has been successfully used for years, allows the production of a PRP with approximately 2.5-fold increased thrombocyte concentration while at the same time reducing leukocytes and erythrocytes.
About Arthrex GmbH:
For over 30 years, Arthrex has been instrumental in the development of new medical treatments. Founded in 1981 in Munich and still privately run today, the company employs more than 4,000 people worldwide in research, development and sales. For more than 10 years, Arthrex has been developing and marketing PRP systems and is one of the world's leading companies in this field.
For more information about Arthrex GmbH, please visit www. Arthrex.com and at www.arthrex-celltherapy.com